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management of hyperphosphatemia in patients
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Background: This short-term study assessed the efficacy and safety of lanthanum carbonate in the treatment of
hyperphosphatemia in dialysis patients; here, we report a prespecified subgroup analysis of patients undergoing
peritoneal dialysis.
Methods: Men and women (n = 39) who had received continuous ambulatory peritoneal dialysis for chronic
kidney disease for 6 months or more were enrolled in eight renal medicine departments in the United Kingdom.
A 2-week washout period was followed by a 4-week dose-titration phase during which patients received
lanthanum carbonate titrated up to 2250 mg/day. This was followed by a 4-week, randomized, placebo-controlled,
parallel-group phase during which patients continued to receive either lanthanum carbonate at the titrated dose,
or a matched dose of placebo. The main outcome measure was control of serum phosphate levels (1.3-1.8 mmol/l)
at the end of the parallel-group phase.
Results: Serum phosphate was controlled in 3/39 (8%) patients at the beginning of the dose-titration phase (after
washout) and in 18/31 (58%) patients treated with lanthanum carbonate at its end. After the parallel-group phase,
60% of lanthanum carbonate-treated patients and 10% of those receiving placebo had controlled serum phosphate.
There was no difference in mean (95% confidence interval) serum phosphate levels between groups at
randomization: lanthanum carbonate, 1.57 (1.34-1.81) mmol/l; placebo, 1.58 (1.40-1.76) mmol/l (p = 0.96). However,
a difference was seen at the end of the parallel-group phase: lanthanum carbonate, 1.56 (1.33-1.79) mmol/l;
placebo, 2.25 (1.81-2.68) mmol/l (p = 0.0015). There were no clinically important changes in nutritional parameters
and no serious treatment-related adverse events were recorded.
Conclusions: At doses up to 2250 mg/day, lanthanum carbonate is well tolerated and controls hyperphosphatemia
effectively. Treatment with higher doses of lanthanum carbonate may allow patients undergoing peritoneal dialysis
the potential to increase their dietary protein intake without compromising their phosphate control.
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Up to 80% of patients with chronic kidney disease
(CKD) stage 5 have levels of serum phosphate above the
normal range (0.8-1.5 mmol/l) [1]. Hemodialysis or
peritoneal dialysis are typically used as part of the man-
agement strategy in patients with CKD stage 5, but even
with regular dialysis, serum phosphate often exceeds
2.1 mmol/l [2], a level associated with increased morbid-
ity and mortality [3,4]. Restricting the intake of dietary
phosphate to 800–1000 mg/day is recommended [5] to
help manage hyperphosphatemia. However, care must be
taken to maintain adequate protein intake because poor
nutrition is also associated with increased mortality [6].
Recent reimbursement changes in the US healthcare
system may result in greater use of peritoneal dialysis
[7]. Malnutrition and comorbidities (including cardio-
vascular disease, chronic respiratory or liver disease, and
carcinoma) are independently associated with mortality
in patients undergoing peritoneal dialysis, and these two
factors in combination are associated with the worst
outcomes [8]. Protein loss across the peritoneal mem-
brane during peritoneal dialysis places a greater nutri-
tional burden on patients compared with those on
hemodialysis, and this loss of protein is exacerbated by
peritonitis, a major complication of peritoneal dialysis
[9]. Maintaining adequate protein intake is therefore an
important part of the management strategy for patients
undergoing peritoneal dialysis. However, protein intake
can be impeded by poor appetite, and increasing dietary
protein can place an increased phosphate burden on the
patient [10].
Poor appetite can be a side effect of peritoneal dialysis.
Patients using a dialysate that contains dextrose, are
exposed to an increased glucose load of 40–80 g/day
[11]. This can result in both early satiety and
gastroparesis [12], which, combined with compression of
the stomach caused by the dialysate, lead to appetite
suppression. Anorexia can also be caused by uremia,
which can be a consequence of under dialysis [9]. Further-
more, patients undergoing peritoneal dialysis can develop
dyslipidemia, because the high glucose load stimulates
synthesis of hepatic lipoprotein [13] and increases insulin
levels [14].
The importance of maintaining adequate dietary pro-
tein intake in patients undergoing peritoneal dialysis was
highlighted in a recent study [15]. A daily protein intake
of more than 0.94 g/kg/day was associated with the best
outcomes in terms of both all-cause and cardiovascular
mortality, and incidence of first-episode peritonitis,
whereas an intake of less than 0.73 g/kg/day was
associated with the worst outcomes. One way to manage
the additional phosphate burden that results from
increased protein intake [10] is concomitant use of a
phosphate binder. Lanthanum carbonate is a highlyeffective phosphate binder [16] with demonstrated effi-
cacy in patients receiving renal replacement therapy
[17]; however, little has been published on its efficacy in
managing hyperphosphatemia in patients undergoing
peritoneal dialysis. Here, we report the results of a
prespecified subgroup analysis of a previously published
phase 2 study [18] in which the efficacy of lanthanum
carbonate was assessed in patients undergoing continu-
ous ambulatory peritoneal dialysis.
Methods
Patients
Men and women were eligible to enter the study if they
were aged 18 years or over, had undergone continuous
ambulatory peritoneal dialysis for 6 months or more,
and had serum phosphate levels consistently above
1.8 mmol/l following washout of previous phosphate
binders. Exclusion criteria included: patients with serum
calcium levels above the upper limit of the normal
range; severe hyperparathyroidism (parathyroid hormone
[PTH] levels > 53 pmol/l (500 ng/l) [5]); serum phos-
phate levels > 3.0 mmol/l after the washout phase; other
clinically significant abnormal laboratory values; a posi-
tive pregnancy test; significant gastrointestinal disorders
(including known active peptic ulcer, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome, and past or
present gastrointestinal malignancies); unstable dietary
habits; life-threatening malignancy; or a positive status
for human immunodeficiency virus. Patients with a his-
tory of drug or alcohol abuse, or who, in the opinion of
the investigators, were unlikely to comply with treat-
ment requirements, were also excluded. Patients were
withdrawn if their serum phosphate levels exceeded
3.0 mmol/l, or if it was felt that continuation would be
detrimental to them. The trial was conducted in accord-
ance with the Guideline for Good Clinical Practice, and
with the Declaration of Helsinki and its subsequent
revisions. Ethical approval of the final protocol and its
amendments was granted by the South and West
Multicentre Research and Ethics Committee. Written
informed consent was given by all patients.
Study design
This was a phase 2, multicenter, double-blind, placebo-
controlled, parallel-group, dose-ranging study with a
washout phase and two treatment phases (Figure 1).
Patients did not receive any phosphate binder medica-
tion during the 2-week washout phase that followed
screening. At the end of the washout phase, patients
whose serum phosphate levels exceeded 1.8 mmol/l
entered a 4-week, open-label phase, in which their
dose of lanthanum carbonate (FOSRENOLW, Shire
Pharmaceuticals, Nyon, Switzerland) was titrated to at-
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Figure 1 Patient flow. Dose-titration and parallel-group phases include patients in the safety set. LC: lanthanum carbonate; R: randomization.
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doses were adjusted weekly according to patients’ serum
phosphate levels, from an initial daily dose of 375 mg up
to a maximum of 2250 mg.
A pilot cohort, consisting of five patients at one study
center, was recruited to complete only the washout and
dose-titration phases before patients were recruited into
the full study. Data from the pilot cohort were reviewed
to establish whether the proposed doses of lanthanum
carbonate were consistent with acceptable safety and
efficacy in patients with chronic renal failure prior to
recruitment for the full study commencing at all centers.
On completion of the dose-titration phase, patients in
the full study entered a 4-week, double-blind, placebo-
controlled, parallel-group phase and were randomized in
a 1:1 ratio to receive either their maintenance dose of
lanthanum carbonate (as determined in the dose-
titration phase) or a matched dose of placebo. There was
no washout between the dose-titration and parallel-
group phases.
Patients’ diets were monitored during the study using
diet sheets and diary cards to confirm consistency of
phosphate intake. Vitamin D was not initiated during
the study, but continuation was allowed at an unchanged
dose. Blood samples were collected at the start of the
dose-titration phase and patients were assessed on a
weekly basis throughout the study for changes in serum
phosphate level. All patients received lanthanum carbon-
ate as chewable tablets (125 or 250 mg), with the daily
dose divided equally among three meals.
Assessments
The primary efficacy endpoint, measured at the end of
the parallel-group phase, was serum phosphate level in
the range 1.3-1.8 mmol/l. Secondary endpoints included
biochemical and hematological parameters and adverse
events. Body weight, serum protein and serum albumin,
are presented as measures of nutritional status. Weekly
pill counts were performed to assess compliance to
study medication.Analysis sets
Data were analyzed from patients who commenced dose
titration (the safety set, including patients from the pilot
cohort), all patients who were randomized to receive
lanthanum carbonate or placebo (the randomized set),
or all patients who received at least one dose of study
medication in the parallel-group phase and had no
protocol violations (the per protocol set).
Statistical analysis
Treatment groups were compared with respect to con-
tinuous data using analysis of variance, Student’s t-test
or Wilcoxon rank-sum test, as appropriate. Frequency
distributions were tested using chi-squared or Fisher’s
exact tests. The final titrated dose was compared be-
tween groups using the Wilcoxon rank-sum test. Treat-
ment groups were compared with respect to serum
phosphate, calcium and PTH levels using analysis of co-
variance, with the value at the end of the dose-titration
phase used as covariate. Data relating to safety and toler-
ability, such as laboratory measures and vital signs, were
tabulated and listed. Data at the end of the parallel-
group phase were summarized both for week 4 and ‘last
visit’. If the week 4 visit was missed, data from the last
visit were carried forward.
Role of the funding organization
The analysis reported here and the study from which the
data are derived, were funded by Shire Pharmaceuticals
(Basingstoke, UK). Three of the authors are employees of
Shire Pharmaceuticals, and approval for publication was




Of the 45 patients undergoing continuous ambulatory
peritoneal dialysis who were screened, six were excluded
from entering the dose-titration phase because their
serum phosphate levels were 1.8 mmol/l or less at the
end of the washout phase; the remaining 39 patients
Table 1 Patient baseline demographics; safety set
Dose-titration
phase (n = 39)
Parallel-group phase
Lanthanum carbonate (n = 10) Placebo (n = 11)
Sex, n (%)
Male 30 (76.9) 6 (60.0) 8 (72.7)
Female 9 (23.1) 4 (40.0) 3 (27.3)
Ethnicity, n (%)
Asian 1 (2.6) 0 (0.0) 0 (0.0)
Caucasian 38 (97.4) 10 (100.0) 11 (100.0)
Age, yearsa 53.4 (15.6) 51.5 (17.5) 54.4 (15.3)
Duration of renal disease, yearsb 5.0 (1.0-41.0) 4.0 (1.0-21.0) 9.0 (1.0-41.0)
Duration of dialysis, monthsb 17.0 (6.0-107.0) 11.0 (6.0-87.0) 13.0 (6.0-107.0)
Previous transplant, n (%) 8 (20.5) 2 (20.0) 3 (27.3)
aMean (standard deviation).
bMedian (minimum, maximum).
Table 2 Dose of lanthanum carbonate at the end of the









375 5 (12.8) 1 (10.0) 0 (0.0)
750 11 (28.2) 3 (30.0) 4 (36.4)
1500 14 (35.9) 3 (30.0) 4 (36.4)
2250 9 (23.1) 3 (30.0) 3 (27.3)
Data are presented as n (%).
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the safety set. There were eight withdrawals during dose
titration: three due to adverse events, two to adverse
events and withdrawal requests made by the patients, one
to protocol violation, one to a serum phosphate level
> 3.0 mmol/l, and one to a serum PTH level > 53 pmol/l
(500 ng/l). Of the 31 patients who completed the dose-
titration phase, five were excluded from the parallel-group
phase following participation in the pilot cohort, three
were excluded because their serum phosphate was uncon-
trolled, and two were withdrawn because of protocol
violations. The remaining 21 patients were randomized to
enter the parallel-group phase (lanthanum carbonate,
n = 10; placebo, n = 11). Baseline characteristics for patients
in the two groups were similar and are shown for all
patients in Table 1. One patient in the placebo group was
excluded from the per protocol set because of a protocol
violation (serum phosphate level > 1.8 mmol/l on entry to
the dose-titration phase). In addition, one patient in the
placebo group discontinued during the parallel-group phase
because of an adverse event.
The level of compliance with study medication was
very high; mean compliance during the parallel-group
phase was at least 95% for patients treated with lan-
thanum carbonate and at least 94% for patients receiving
placebo. There were no marked differences in compli-
ance for any visit.
Phosphate control
The final titrated doses of lanthanum carbonate for all
patients are given in Table 2; there was no significant
difference in the final titrated doses between the groups
entering the parallel-group phase (p = 0.85). At the start
of the dose-titration phase, three patients (8%) had con-
trolled serum phosphate and by the end of this phase,serum phosphate was controlled in 18 patients (58%). At
the start of the parallel-group phase, seven (70%) of the
patients randomized to each treatment group (n = 10 in
each group; per protocol set) had controlled serum
phosphate. At the end of this phase, six patients (60%)
had controlled serum phosphate in the lanthanum car-
bonate group, compared with one (10%) in the placebo
group (p = 0.057).
At the end of the dose-titration phase, the mean (95%
confidence interval [CI]) serum phosphate level was 1.68
(1.54-1.81) mmol/l, compared with 2.23 (2.14-2.32)
mmol/l at the start of the phase (Figure 2A). There was
no significant difference in mean (95% CI) serum phos-
phate levels between the groups after randomization (the
start of the parallel-group phase): lanthanum carbonate,
1.57 (1.34-1.81) mmol/l; placebo, 1.58 (1.40-1.76) mmol/l;
(p = 0.96). After 1 week, the mean (95% CI) serum phos-
phate level in the placebo group was 2.02 (1.85-2.20)
mmol/l and by the end of this phase the difference
between the groups was significant: lanthanum carbonate,
1.56 (1.33-1.79) mmol/l; placebo, 2.25 (1.81-2.68) mmol/l;






















































































Figure 2 Serum phosphate levels. (A) during the open-label,
lanthanum carbonate dose-titration phase (safety set); (B) during the
randomized, placebo-controlled, parallel-group phase (per protocol
set). *p < 0.01 vs placebo. Data are presented as mean ± 95%
confidence interval.
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Phosphate intake was derived from diary data, and the
median intake was comparable between the two groups.
At the end of the parallel-group phase, median daily phos-
phate intake was 34.75 mmol (1075.6 mg as phosphorus)
in the lanthanum carbonate group and 32.57 mmol
(1008.0 mg as phosphorus) in the placebo group. Further-
more, no clinically important changes in body weight or
nutritional parameters were observed (Table 3). There wasa small reduction in mean body weight, but mean serum
albumin and total serum protein levels were stable during
the dose-titration phase. During the parallel-group phase,
the mean levels for body weight, total serum protein and
serum albumin remained stable, or increased slightly in
the lanthanum carbonate group, whereas all three were
slightly reduced in the placebo group.Serum chemistry
There were no significant changes in mean serum calcium
levels during the study. Mean (95% CI) levels of serum cal-
cium were 2.32 (2.24-2.40) mmol/l on entry to the dose-
titration phase and 2.38 (2.30-2.47) mmol/l at the end of
this phase. There was no significant difference in mean
serum calcium levels between the groups after
randomization: lanthanum carbonate, 2.34 (2.18-2.49)
mmol/l; placebo, 2.45 (2.23-2.68) mmol/l; (p = 0.350),
and no significant difference between the groups at
the end of the parallel-group phase: lanthanum carbonate,
2.36 (2.18-2.53) mmol/l; placebo, 2.42 (2.30-2.54) mmol/l;
(p = 0.987). A small increase in mean serum PTH levels
was seen in the placebo group during the parallel-group
phase, but the difference between treatment groups was
not statistically significant: mean (95% CI) change during
the parallel-group phase: lanthanum carbonate, (0.39
(−3.00-3.78) pmol/l (3.67 [−28.27-35.61] ng/l); placebo, 4.57
(−0.72-9.86) pmol/l (43.11 [−6.74-92.96] ng/l); p = 0.148).Safety
There were no deaths or serious treatment-related ad-
verse events during the study. Five patients were with-
drawn during dose titration with lanthanum carbonate
because of adverse events. Three of these were thought
likely to be treatment-related (two with nausea and
one with retrosternal pain), and two unlikely to be
treatment-related (one with shoulder pain and one with
menorrhagia). One patient was withdrawn while receiv-
ing placebo (anaphylactic shock following intraperitoneal
treatment with vancomycin for peritonitis). During the
dose-titration phase, 34 patients (87%) experienced at
least one adverse event. In the parallel-group phase, seven
patients (70%) in the lanthanum carbonate group and eight
patients (73%) in the placebo group experienced at least
one adverse event. The most commonly reported adverse
events during dose titration included: vomiting, 10 (26%);
nausea, 9 (23%); diarrhea, 3 (8%); and itching, 3 (8%). The
adverse events most commonly reported by body system in
both the lanthanum carbonate and placebo groups during
the parallel-group phase were gastrointestinal (Table 4),
and the only events reported by preferred term more than
once in any body system were localized infection (2 [20%],
lanthanum carbonate group) and coughing (2 [18%],
placebo group).
Table 3 Nutritional parameters; safety set
Dose-titration
phase (n = 39)
Parallel-group phase
Lanthanum carbonate (n = 10) Placebo (n = 11)
Weight, kg
Start of dose-titration phase 76.2 (14.1) – –
Start of parallel-group phase 74.9 (13.5)a 73.2 (16.0) 74.1 (12.0)
End of parallel-group phase – 73.2 (17.0) 73.4 (13.6)b
Total serum protein, g/dl
Start of dose-titration phase 6.9 (0.8) 6.7 (1.0) 6.9 (0.7)
Start of parallel-group phase 6.8 (0.7)c 6.6 (0.9) 6.9 (0.4)
End of parallel-group phase – 6.9 (0.7) 6.7 (0.7)d
Serum albumin, g/dl
Start of dose-titration phase 3.8 (0.4) 3.7 (0.4) 4.0 (0.3)
Start of parallel-group phase 3.7 (0.3)c 3.6 (0.4) 3.9 (0.3)
End of parallel-group phase – 3.7 (0.4) 3.6 (0.4)e
Data are presented as mean (standard deviation).
an = 25; bn = 9; cn = 31; dn = 7; en = 8.
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This short-term clinical study demonstrates that lan-
thanum carbonate is an effective option for the control
of serum phosphate in patients undergoing continuous
ambulatory peritoneal dialysis. Of the 45 patients
screened, six had a serum phosphate level of 1.8 mmol/l
or less after washout and were thus excluded prior to
dose titration. The use of food diaries was implemented
during the washout phase so this may have reinforcedTable 4 Adverse events; safety set
Dose-titration
phase (n = 39)
Patients with any AE, n (%) 34 (87.2)
Total AEs, n 82
Patients withdrawing because of an AE, n (%) 5 (12.8)
Gastrointestinal AEs by preferred term, n (%) 20 (51.3)a












aSome patients reported more than one gastrointestinal adverse event.
AE: adverse events.the need for dietary control and led to a reduction in
dietary phosphate intake in some patients. Following
washout, 39 patients with uncontrolled serum phosphate
(> 1.8 mmol/l) underwent dose titration with lanthanum
carbonate, and after 4 weeks of treatment, the group
mean serum phosphate level was 1.68 mmol/l, compared
with a mean baseline value (after washout) of 2.23 mmol/l.
During the parallel-group phase, the mean serum phos-
phate level in the placebo group was 2.02 mmol/l afterParallel-group phase
Lanthanum carbonate (n = 10) Placebo (n = 11)
7 (70.0) 8 (72.7)
14 19
– 1 (9.1)
3 (30.0)a 3 (27.3)a
– –
– –









1 (10.0) 1 (9.1)
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in patients receiving lanthanum carbonate (Figure 2). After
4 weeks, the between-group difference in mean serum
phosphate level was statistically significant (p = 0.0015). At
the end of the study, 60% of patients had controlled serum
phosphate in the lanthanum carbonate group compared
with only 10% in the placebo group.
Serum phosphate levels can be managed in dialysis
patients by restricting their intake of phosphate, but this
may limit their intake of dietary protein, thereby com-
promising their nutritional status [6]. Maintenance of
good nutritional status is important in terms of overall
outcome for dialysis patients [7,15], and in those under-
going peritoneal dialysis there is an additional nutritional
burden compared with hemodialysis patients, caused by
serum protein loss across the peritoneal membrane. A
small reduction in mean body weight that was recorded
during the dose-titration phase of this study may have
been caused by dietary adjustments made by patients
trying to standardize their dietary phosphate intake in
response to advice from dietitians. However, during the
parallel-group phase, no change in mean body weight
was seen in the lanthanum carbonate group, and other
measures of nutritional status (mean serum albumin and
total serum protein levels) were also unchanged. In com-
parison, mean body weight, serum albumin concentra-
tion and total serum protein concentration fell slightly
in the placebo group during the parallel-group phase.
Such changes may not be indicative of an overall trend
given the short duration of treatment, but relatively
small changes in serum albumin concentration over a
sustained period can be associated with major changes
in outcome. An increase of 0.3 g/dl or more over a
6-month period has been associated with a significant
reduction in all-cause mortality in patients undergoing
peritoneal dialysis, while a reduction of 0.2 g/dl or
greater over the same period has been associated with a
significant increase in mortality [19].
Lanthanum carbonate was well tolerated in this study;
the majority of adverse events were gastrointestinal and oc-
curred to a similar extent in both randomized groups. This
is in contrast to a recent study in patients on peritoneal dia-
lysis where 15/35 patients on lanthanum carbonate were
withdrawn, 10 of whom had gastrointestinal complications
[20]. Other studies have reported no withdrawals due to
adverse events and variable numbers of mild or moderate
events [21-23]. In the present study adverse events led
5/39 patients to be withdrawn from the dose-titration
phase; three of these were thought likely to be
treatment-related. Levels of serum markers relevant to
CKD (such as calcium and PTH) were essentially un-
changed throughout the study. The maximum daily
dose of lanthanum carbonate used in this study was
2250 mg and most patients received 1500 mg/day orless. This is considerably lower than the daily dose of
3000 mg now used in many countries. At this higher
dose, it would be anticipated that more dietary phos-
phate could be removed and, therefore, if patients
were to receive lanthanum carbonate at this dose they
may have the potential to improve their nutritional
status by increasing their dietary protein intake with-
out compromising serum phosphate control. While
not clinically important, the mean levels of serum
albumin observed (as a marker of nutritional status)
were slightly below the level of 4 g/dl that is recom-
mended in maintenance dialysis patients [24].
Increasing the dose of a medication is usually associated
with an increase in tablet burden, a factor that is an im-
portant consideration in a patient group in which thera-
peutic regimens are demanding. However, lanthanum
carbonate can be given at a dose of 3000 mg/day in three
tablets, so the daily dose can be increased to this level
without increasing tablet burden. A recent study found
that when patients switched from another phosphate
binder to lanthanum carbonate, their daily tablet burden
was reduced by approximately 2–8 tablets [25].
Oral phosphate binders alone are unlikely to fully con-
trol serum phosphate levels, and must be administered
in conjunction with a careful review of peritoneal dialy-
sis adequacy and prescription, as well as dietetic review
and counselling to ensure that dietary intake is con-
trolled. These three measures taken together will provide
optimal phosphate control in the majority of cases.
Potential limitations of this study, relating to possible
bias introduced by exclusion criteria and the protocol
for withdrawals from the trial, were considered and
placed in context in a previous publication [18].
Additional limitations include the short duration of the
study and the small number of patients following
randomization. However, recent longer-term (8–48 week)
studies have demonstrated that lanthanum carbonate
has a phosphate-lowering effect on patients on periton-
eal dialysis [21-23]. A further limitation is that dialysis
adequacy was not assessed throughout the study, and
any between-group differences in this parameter could
contribute to altered phosphate levels.
It is also worth noting that dietary data were collected in
this study primarily for the purpose of ensuring consistency
of dietary phosphate intake. Given the importance of
maintaining adequate nutritional status in patients under-
going peritoneal dialysis, this trial would have benefited
from more extensive data collection on calorie and protein
intake. Given the promising data presented here on the
level of serum phosphate control achievable with a
relatively modest dose of lanthanum carbonate in patients
on peritoneal dialysis, a longer and more detailed investiga-
tion into the nutritional status of such patients receiving
higher doses of lanthanum carbonate may be warranted.
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At doses up to 2250 mg/day, lanthanum carbonate is
well tolerated and controls hyperphosphatemia effect-
ively. Treatment with higher doses of lanthanum carbon-
ate may allow patients undergoing peritoneal dialysis the
potential to increase their dietary protein intake without
compromising their phosphate control.
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